ACUTE AND LATE TOXICITY OF PELVIC RADIOTHERAPY AND CONCOMITANT HYPOFRACTIONATED IMRT BOOST COMBINED WITH HORMONAL THERAPY FOR HIGH-RISK PROSTATE CANCER

被引：0
|
作者：
Quon, H. [1 ]
Loblaw, A. [1 ]
Morton, G. [1 ]
Sixel, K. [1 ]
Pang, G. [1 ]
Basran, P. [2 ]
Szumacher, E. [1 ]
Danjoux, C. [1 ]
Choo, R. [3 ]
Thomas, G. [1 ]
Kiss, A. [1 ]
Deabreu, A. [1 ]
Cheung, P. [1 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Odette Canc Ctr, Toronto, ON, Canada
[3] Mayo Clin, Rochester, NY USA
来源：
RADIOTHERAPY AND ONCOLOGY | 2010年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
143
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [31] Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, survival, and late toxicity outcomes
    Loblaw, Andrew
    Musunuru, Bindu
    Cheung, Patrick
    Vesprini, Danny
    Liu, Stanley K.
    Chu, William
    Chung, Hans T.
    Morton, Gerard
    Deabreu, Andrea
    Davidson, Melanie
    Ravi, Ananth
    Helou, Joelle
    Ho, Ling
    Zhang, Liying
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] Whole Pelvic Radiotherapy With Hypofractionated Simultaneous Integrated Boost And Hormonal Therapy For NCCN High Risk Prostate Adenocarcinoma: Implications For The Alpha/Beta Ratio
    McDonald, A. M.
    Dobelbower, M. C.
    Jacob, R.
    Kim, R. Y.
    Wu, X.
    Fiveash, J. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S416 - S417
  • [33] Postoperative Pelvic Hypofractionated Accelerated Radiotherapy with Cytoprotection (HypoARC) for High-risk or Recurrent Prostate Cancer
    Koukourakis, Michael I.
    Papadopoulou, Aikaterini
    Abatzoglou, Ioannis
    Panteliadou, Marianthi
    Sismanidou, Kyriaki
    Touloupidis, Stavros
    ANTICANCER RESEARCH, 2012, 32 (10) : 4561 - 4568
  • [34] IMRT simultaneous integrated boost for high-risk prostate cancer
    Li, X
    Wang, JZ
    Jursinic, P
    Lawton, CA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S632 - S633
  • [35] Risk factors for acute toxicity in prostate cancer patients receiving hypofractionated IMRT
    Matrone, F.
    Montesi, G.
    Saldi, S.
    Bellavita, R.
    Frattegiani, A.
    Lupattelli, M.
    Zucchetti, C.
    Cusco, S.
    Bini, V.
    Aristei, C.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S680 - S681
  • [36] IMRT Sliding Window vs. RapidArc: Comparison of Acute and Late Toxicity of Pelvic IMRT for Prostate Cancer with high Risk Profile
    Hentschel, B.
    Strauss, D.
    Berger, K.
    Oehler, W.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 29 - 29
  • [37] Acute and late toxicity of hypofractionated RT for localized prostate cancer: IMRT vs Tomotherapy
    Rese, A.
    Pastore, F.
    Panelli, G.
    Pepe, A.
    Toledo, D.
    Francomacaro, F.
    Iorio, V.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S822 - S822
  • [38] Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer
    Pinitpatcharalert, Attapol
    Happersett, Laura
    Kollmeier, Marisa
    McBride, Sean
    Gorovets, Daniel
    Tyagi, Neelam
    Varghese, Melissa
    Zelefsky, Michael J.
    ADVANCES IN RADIATION ONCOLOGY, 2019, 4 (02) : 337 - 344
  • [39] Pelvic proton radiotherapy for high-risk prostate cancer
    Chera, B. S.
    Vargas, C.
    Flampouri, S.
    Morris, C. G.
    Yeung, D.
    Olivier, K.
    Duvvuri, S.
    Li, Z.
    Mendenhall, N. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S326 - S326
  • [40] ACUTE TOXICITY IN HIGH-RISK PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN SUPPRESSION AND HYPOFRACTIONATED INTENSITY-MODULATED RADIOTHERAPY
    Pervez, Nadeem
    Small, Cormac
    MacKenzie, Marc
    Yee, Don
    Parliament, Matthew
    Ghosh, Sunita
    Mihai, Alina
    Amanie, John
    Murtha, Albert
    Field, Colin
    Murray, David
    Fallone, Gino
    Pearcey, Robert
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (01): : 57 - 64
12345